Paul Kelly has been appointed CEO of Orchid Biosciences, filling a position that has been left vacant since Dale Pfost resigned as CEO in December 2002.
Kelly comes to Orchid from software company OmniViz, where he was CEO. He was previously a co-founder and CEO of Gemini Genomics, a UK-based population genetics firm that was acquired by Sequenom in 2001.
Bernd R. Seizinger, CEO and president of GPC Biotech, has been appointed to the board of directors at Heidelberg, Germany-based chemical genomics company Graffinity Pharmaceuticals.
Seizinger has held his executive position at Martinsried, Germany-based GPC Biotech since 1998. Prior to that, he was executive vice president and chief scientific officer at Genome Therapeutics. He also has worked in senior positions at Bristol-Myers Squibb’s Pharmaceutical Research Institute, and as an associate professor of neuroscience at Harvard Medical School and director of the Molecular Neuro-Oncology Laboratory at Massachusetts General Hospital.
Renowned human geneticist Ming Tsuang has been named director of the University of California San Diego’s new Institute of Behavioral Genomics.
Tsuang is a professor of psychiatry at Harvard Medical School and is director of the Harvard Institute of Psychiatric Epidemiology and Genetics and the Harvard Department of Psychiatry at the Massachusetts Mental Health Center.